Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: Clinical, pharmacokinetic, and pharmacodynamic outcomes

Transplantation

Volumn 83, Issue 4, 2007, Pages 417-424

  Budde, Klemens ^a,e   Glander, Petra ^a   Krämer, Bernhard K ^b   Fischer, Wolfgang ^c   Hoffmann, Ute ^b   Bauer, Steffen ^a   Grohmann, Jana ^a   Neumayer, Hans Hellmut ^a   Arns, Wolfgang ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Enteric coated mycophenolic acid; Inosine monophosphate dehydrogenase; Mycophenolate mofetil; Mycophenolate sodium; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CORTICOSTEROID; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BRAIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETIC FOOT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; ENTERIC COATED TABLET; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEART ARRHYTHMIA; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; SUBDURAL HEMATOMA; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; DRUG EFFECT; DRUG TOLERANCE; DRUG TOXICITY; GRAFT REJECTION; IMMUNOLOGY; KIDNEY; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; DRUG TOLERANCE; DRUG TOXICITY; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; TREATMENT OUTCOME;

EID: 33947509088     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000251969.72691.ea     Document Type: Article

References (25)

1. Millan O, Oppenheimer F, Brunet M, et al. Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clin Chem 2000; 46: 1376.
2. Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005; 19: 199.
3. Salvadori M, Holzer H, de Mattos A, et al. on behalf of the ERL B301 Study Group. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231.
4. Salvadori M, Holzer H, Civati G, et al. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS, Myfortic) is safe in kidney transplant patients. Clin Nephrol 2006; 66: 112.
5. Budde K, Curtis J, Knoll G, et al. on behalf of the ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safety administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237.
6. Budde K, Knoll G, Curtis J, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (ECMPS, myfortic). Clin Nephrol 2006; 66: 102.
7. Abbud-Filho M, Girón F, Hernández EP, et al. Myproms Latam Study Group. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: interim results of a multicenter Latin American study. Transplant Proc 2004; 36: 1647.
8. Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant patients: Results of a 12-months, single-blind, randomized, parallel group, multicenter study. J Heart Lung Transplant 2006; 25: 935.
9. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisolone versus tacrolimus/prednisolone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67: 411.
10. Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Transplantation 2000; 69: 875.
11. Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60: 225.
12. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
13. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5: 225.
14. Kaplan B, Meier-Kriesche H-U, Minnick P, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant 2005; 19: 551.
15. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119.
16. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5: 987.
17. Shipkova M, Armstrong VW, Kuypers D, et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit 2001; 23: 717.
18. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000; 14: 100.
19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
20. Glander P, Braun KP, Hambach P, et al. Non-radioactive determination of inosine 5′-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001; 34: 543.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
22. Tedesco-Silva H, Bastien M-C, Choi L, et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc 2005; 37: 852.
23. Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004; 5: 1333.
24. Pawinski T, Hale M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 1497.
25. van Gelder T, Shaw L. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005; 80: S244.